作者: Valeria Bruno , Giuseppe Battaglia , Agata Copani , Giacomo Casabona , Marianna Storto
DOI: 10.1007/978-1-4419-8959-8_6
关键词:
摘要: Metabotropic glutamate (mGlu) receptors, which exert a modulatory effect on excitatory synaptic transmission, are considered as potential targets for neuroprotective drugs and the advent of potent centrally available subtype-selective ligands has lead to an extensive investigation role individual mGlu receptor subtypes in neurodegeneration. Pharmacological blockade mGlu1 or -5 receptors pharmacological activation mGlu2/3 mGlu4/7/8 produces neuroprotection variety vitro vivo models. MGlu1 antagonists promising treatment brain ischemia prophylaxis neuronal damage induced by hyperactivity. MGlu5 may limit hyperactivity NMDA because mGlu5 physically functionally connected membranes, suggesting application chronic neurodegenerative disorders, such Amyotrophic Lateral Sclerosis (ALS) Alzheimer’s disease (AD). MGlu2/3 agonists inhibit release, also promote synthesis release neurotrophic factors astrocytes. These therefore have broad agents eNS disorders. Finally, potently seizure